Thought Leadership
Colin G. Miller, Ph.D., F.I.C.R., CSci, Senior Vice President of Medical Affairs
Dr. Colin G. Miller joined BioClinica, formerly Bio-Imaging Technologies in 1999 as Vice President of Business Development. Prior to joining BioClinica, Dr. Miller was Director of Clinical Services at Bona Fide, a company that was acquired by Bio-Imaging in 1999. Dr. Miller started Bona Fide Ltd in 1994 when he moved from the UK to Madison, Wisconsin. Immediately preceding this move, Dr. Miller served as the head of this Physical Measurements Team, Europe, at Procter & Gamble (P&G) Pharmaceuticals. Dr. Miller holds a BSc (Hons) in Physiology and Zoology from the University of Sheffield, UK, and a Ph.D. from the University of Hull, UK. He is also a Fellow of the Institute of Clinical Research, an associate member of the Radiological Society of North America and a member of the American Society of Bone and Mineral Research. Dr. Miller has written and co-authored over 40 scientific publications and is co-editor of the books "Clinical Trials in Osteoporosis," and “Clinical Trials in Osteoarthritis and Rheumatoid Arthritis,” published by Springer Ltd.
Read some of Dr. Miller's blog posts at BioClinica's Trial Blazers blog.
Klaus Noever, M.D., Vice President of Business Development and Clinical Affairs, Europe and Japan
Dr. Klaus Noever joined BioClinica, formerly Bio-Imaging Technologies, Inc. in 1998 as Director, Business Development Europe. Prior to joining BioClinica, Dr. Klaus Noever was a consultant for medical imaging in clinical drug development in oncology, bone, CNS and cardiovascular diseases. His previous positions were in clinical R&D at Schwarz Pharma, Boehringer Ingelheim and Siemens Medical Systems. Prior to joining the industry, he worked as a physician at the University hospitals of Bochum (radiology) and Erlangen (cardiology) in Germany.
Chahin Pachai, Ph.D., Vice President and Executive Director, Lyon
Dr. Chahin Pachai joined BioClinica, formerly Bio-Imaging Technologies in April of 2007. After attending business and management courses at Ecole Management de Lyon (2001) and prior to joining BioClinica, Chahin founded Theralys in October 2001, an imaging CRO which was acquired by BioClinica, in February 2007. Dr. Chahin Pachai obtained a degree in Electrical and Electronic Engineering from INSA Lyon in 1995, and a Ph.D., in the field of quantitative MRI, image segmentation and CNS diseases in 2000. He was a research fellow at the Surgical Planning Laboratory, Brigham & Women’s Hospital, Harvard Medical School (1997-98).
Harris A. Ahmad, M.D., Medical Director of Medical Affairs
Dr. Harris Ahmad joined BioClinica in 2007 as Medical Director in Medical Affairs at BioClinica, Inc. His primary role is as the therapeutic area lead for BioClinica's Autoimmune and Rheumatic Disease Phase 1b though Phase 4 clinical trials which include Crohn's, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis. He has consulted on and designed Clinical Trial Protocols, Imaging Review Charters, and Statistical Analysis Plans for Regulatory Submissions to both the EMA and FDA. His most recent contributions to the industry include the scientific design and development of several key clinical trials using MRI and X-ray as imaging biomarkers for the approvals of Simponi, Actemra, Humira, Cimzia, Orencia, Remicaide, and Enbrel. Prior to Dr. Ahmad's career with BioClinica, he was in residency training in Diagnostic Radiology and Internal Medicine at Hahnemann University Hospital in Philadelphia, PA, USA. Dr. Ahmad received his MD from Drexel University College of Medicine in 2004 with a distinction as a Humanities Scholar.
Andrzej (Andy) Dzik-Jurasz, M.D., Senior Medical Director for Medical Affairs
Dr. Andy Dzik-Jurasz joined BioClinica in 2011 as Senior Medical Director for Medical Affairs. Dr. Dzik-Jurasz is responsible for leading BioClinica's global oncology strategy, including the development and implementation of new offerings to support our clients' clinical studies. Prior to joining BioClinica, Dr. Dzik-Jurasz was the Executive Director, Global Head Oncology Translational Imaging at Novartis, Vice President of Clinical Development for Point Therapeutics, Head of Imaging for Epix Pharmaceuticals, and Senior Director in Translational Medicine and Technology at GlaxoSmithKline. Dr. Dzik-Jurasz received his medical degree from Westminster Medical School, London, UK, and his Ph.D. from the Institute of Cancer Research, London, UK. He is a Fellow of the Royal College of Surgeons of England and Fellow of the Royal College of Radiologists.